Citizens Jmp Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price

Taysha Gene Therapies (NASDAQ:TSHA) had its target price raised by equities research analysts at Citizens Jmp from $8.00 to $11.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp’s price objective would suggest a potential upside of 68.45% from the stock’s current price.

A number of other brokerages have also recently weighed in on TSHA. Needham & Company LLC restated a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Friday, March 27th. Citigroup reissued an “outperform” rating on shares of Taysha Gene Therapies in a research report on Tuesday. Truist Financial upgraded Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Bank of America reaffirmed a “buy” rating on shares of Taysha Gene Therapies in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of “Buy” and a consensus target price of $11.91.

Taysha Gene Therapies Price Performance

TSHA opened at $6.53 on Tuesday. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -17.18 and a beta of 1.19. The stock has a fifty day simple moving average of $5.98 and a two-hundred day simple moving average of $5.25. Taysha Gene Therapies has a 12-month low of $2.25 and a 12-month high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Research analysts predict that Taysha Gene Therapies will post -0.5 earnings per share for the current fiscal year.

Insider Activity at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the sale, the insider owned 1,136,410 shares in the company, valued at $5,068,388.60. This represents a 14.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.78% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd increased its holdings in shares of Taysha Gene Therapies by 143.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock worth $43,000 after purchasing an additional 4,607 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in shares of Taysha Gene Therapies during the fourth quarter valued at $59,000. Guggenheim Capital LLC purchased a new stake in shares of Taysha Gene Therapies during the fourth quarter valued at $61,000. R Squared Ltd bought a new stake in Taysha Gene Therapies in the 1st quarter worth about $50,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in Taysha Gene Therapies in the 1st quarter worth about $51,000. 77.70% of the stock is owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.